Pfizer
Pfizer to pay $784.6 million fine due to Wyeth Medicaid fraud
April 28, 2016Medical Communications, Sales and Marketing False Claims Act, Medicaid, Pfizer, US, Wyeth, department, fraud, insurer, justice
Pfizer has agreed to pay $784.6 million in a settlement with the US Department of Justice, relating to false and …
New head of R&D at Biogen
April 27, 2016Research and Development Biogen, Pfizer, R&D, erhlers, michael, michael erhlers, research and development
Biogen (NASDAQ: BIIB) has announced the appointment of Dr Michael Ehlers as executive vice president, research and development. His role …
Eisai poaches senior Pfizer and Sanofi execs for neurology group
April 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Pfizer, Sanofi, appointments, hawthorne, zaim
Eisai has made new appointments to its US neurology business group, bringing in senior executives who have previously held positions …
Pfizer fined for epilepsy drug price increase by UK antitrust regulator
April 15, 2016Medical Communications CMA, Flynn Pharma, Pfizer, antitrust, competition and markets authority, epilepsy, fine, flynn
Pfizer has been fined for unfairly increasing the price of epilepsy drug Epanutin (phenytoin sodium) by the UK Competition and …
Focus: Ovarian cancer and the case of elusive cure
April 12, 2016Research and Development J&J, JJ, Pfizer, drug trials, ovarian cancer
Each year, more than 21,000 women in the US are diagnosed with ovarian cancer, according to research and more than …
Pfizer, IBM partner to develop monitoring system for Parkinson’s disease
April 8, 2016Medical Communications, Research and Development Parkinson's disease, Pfizer, collaboration, ibm, research, technology
US pharma giant Pfizer (NYSE: PFE) and International Business Machines Corp (NYSE: IBM) have partnered on a research project focussed on …
Shire reassures Baxalta acquisition on track in the aftermath of Pfizer-Allergan breakup
April 7, 2016Business Services, Sales and Marketing AbbVie, Allergan, Baxalta, Deals, Financial, Merger & Acquisition, Pfizer, Shire
Ireland-headquartered Shire Plc (LSE: SHP) has reassured its $32-billion merger deal with US-based Baxlata (NYSE: BXLT) remains on track in …
5 things to know about the Pfizer/Allergan inversion collapse
April 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 5, 5 things, Allergan, Pfizer, collapse, inversion, reasons
The end came very quickly for the Pfizer/Allergan $160 billion deal once the US Treasury Department announced a new set …
Pfizer to call off $160 billion merger with Allergan
April 6, 2016Business Services, Research and Development, Sales and Marketing Allergan, Pfizer, deal, legal, merger and acquisition, regulation
US pharma giant Pfizer Inc (NYSE: PFE) has decided to terminate the $160 billion merger with Botox-maker Allergan Plc (NYSE: …
Phase III trial initiated in Merck and Pfizer partnership for renal cell carcinoma drug
April 6, 2016Research and Development Merck, Pfizer, avelumab, carcinoma, inlyta, javelin, partnership, phase III, renal
The first patient has been treated in the Phase III clinical trial, which sees Merck (ETR: MRK) and Pfizer (NYSE: …
Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial
April 5, 2016Medical Communications, Research and Development, Sales and Marketing Allergan, Pfizer, Xeljanz, merger, phase III, psoriatic arthritis, tofacitinib
Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial …
Pfizer’s cholesterol-lowering bococizumab shows promise in Phase III trials
April 1, 2016Research and Development, Sales and Marketing Pfizer, bococizumab, lipid, phase 3, phase III, spire, spire-ai
Pfizer (NYSE: PFE) has announced positive top line results from the SPIRE-AI Phase III clinical trial evaluating bococizumab. This protein …
Fake press release on drug pricing “erroneously attributed” to Pfizer
April 1, 2016Medical Communications Pfizer, fake, false, legal action, press release, washington post
Pfizer (NYSE: PFE) has issued a statement on a false press release related to drug pricing that was reported on …
EMA to review Pfizer’s Xeljanz for patients with rheumatoid arthritis
March 24, 2016Research and Development, Sales and Marketing EMA, Pfizer, Xeljanz, approval, authorisation, marketing, review, rheumatoid arthritis
Pfizer (NYSE: PFE) has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) …
Pfizer’s JAK inhibitor meets endpoints in Phase III ulcerative colitis trials
March 21, 2016Research and Development, Sales and Marketing JAK inhibitor, Pfizer, ecco, endpoint, octave, tofacitinib, ulcerative colitis
Pfizer (NYSE:PFE) has announced that investigational JAK inhibitor – oral tofacitinib – met the primary and secondary endpoints in two …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
